Sweat Rate Measurement With a Sensor (Wearable) in Different Climatic Conditions With Road Cyclists. (CYSU)

June 21, 2024 updated by: Francisco Javier López Román, Universidad Católica San Antonio de Murcia
Controlled, double-blind, crossover clinical trial with six parallel arms depending on the combination of temperature and humidity (22º and 40% humidity, 35º 40% humidity and 35º and 65% humidity), with two differents intensity, to investigate and validate the physiological use of a sensor in recreational road cyclists.

Study Overview

Detailed Description

Subjects who meet the inclusion criteria will be recruited to participate in the clinical trial and perform the exercise sessions.

The cyclists in the study will have to make 7 visits to the laboratory. At the first visit, their aerobic performance will be evaluated by an incremental test to exhaustion with gas analysis. And in the next 6 visits they will have to perform a sustained intensity exercise with different environmental conditions according to the combination of temperature, humidity and intensity.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Murcia, Spain, 30107
        • Catholic University of Murcia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male cyclists with more than two years of cycling experience.
  • Perform tests without fatigue.
  • Road bike training at least twice a week.

Exclusion Criteria:

  • Participants with chronic illness.
  • Have a long-term injury that prevents you from training in the previous month.
  • Inability to understand informed consent.
  • Use of diuretics in the month prior to or during the measurement period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 22 degrees, 40% humidity and 50% intensity

The room in which the 30-minute test will be performed will be at 22 degrees Celsius and 40% humidity.

The subject should perform the test at 50% of the power at which he reached his VO2max.

The subject will perform the 30-minute test at an intensity of 50% of the power at which he/she has reached his/her VO2max.
The performance test will be carried out in a room conditioned to a temperature of 22º.
The performance test will be carried out in a room conditioned to 40% humidity.
Experimental: 35 degrees, 40% humidity and 50% intensity

The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 40% humidity.

The subject should perform the test at 50% of the power at which he reached his VO2max.

The subject will perform the 30-minute test at an intensity of 50% of the power at which he/she has reached his/her VO2max.
The performance test will be carried out in a room conditioned to 40% humidity.
The performance test will be carried out in a room conditioned to a temperature of 35º.
Experimental: 35 degrees, 65% humidity and 50% intensity

The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 65% humidity.

The subject should perform the test at 50% of the power at which he reached his VO2max.

The subject will perform the 30-minute test at an intensity of 50% of the power at which he/she has reached his/her VO2max.
The performance test will be carried out in a room conditioned to a temperature of 35º.
The performance test will be carried out in a room conditioned to 65% humidity.
Experimental: 22 degrees, 40% humidity and 60% intensity

The room in which the 30-minute test will be performed will be at 22 degrees Celsius and 40% humidity.

The subject should perform the test at 60% of the power at which he reached his VO2max.

The performance test will be carried out in a room conditioned to a temperature of 22º.
The performance test will be carried out in a room conditioned to 40% humidity.
The subject will perform the 30-minute test at an intensity of 60% of the power at which he/she has reached his/her VO2max.
Experimental: 35 degrees, 40% humidity and 60% intensity

The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 40% humidity.

The subject should perform the test at 60% of the power at which he reached his VO2max.

The performance test will be carried out in a room conditioned to 40% humidity.
The performance test will be carried out in a room conditioned to a temperature of 35º.
The subject will perform the 30-minute test at an intensity of 60% of the power at which he/she has reached his/her VO2max.
Experimental: 35 degrees, 65% humidity and 60% intensity

The room in which the 30-minute test will be performed will be at 35 degrees Celsius and 65% humidity.

The subject should perform the test at 60% of the power at which he reached his VO2max.

The performance test will be carried out in a room conditioned to a temperature of 35º.
The performance test will be carried out in a room conditioned to 65% humidity.
The subject will perform the 30-minute test at an intensity of 60% of the power at which he/she has reached his/her VO2max.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sweat
Time Frame: Change of baseline rate of sweet rate in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
The amount of sweat will be measured by a sensor placed on the back.
Change of baseline rate of sweet rate in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microcapillary Blood
Time Frame: Change of baseline rate of sweet rate in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
By means of a lancet puncture in the thumb of the finger, 70 ml of capillary blood will be extracted.This test provides biochemical variables (ABL90FLEX) with 70 ml of capillary blood.
Change of baseline rate of sweet rate in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
Heart Rate
Time Frame: Changes of heart rate in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
The heart rate will be evaluated by means of a heart rate strap.
Changes of heart rate in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
Fatigue
Time Frame: Change of fatigue in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
Rate of perceived exertion using Borg scale. En esta escala 0 representa nada fatigado y el 10 esfuerzo máximo.
Change of fatigue in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
Temperature on the forehead
Time Frame: Changes in Temperature on the forehead in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
The temperature will be measured by an infrared thermometer.
Changes in Temperature on the forehead in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
Temperature in the ear
Time Frame: Changes in Temperature in the ear in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
The temperature will be measured by ear thermometer.
Changes in Temperature in the ear in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
Sleep efficiency
Time Frame: Changes in the sleep efficiency in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
Measured by accelerometry, with Actigraph wGT3X-BT
Changes in the sleep efficiency in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
Karolinska drowsiness scale
Time Frame: It will be measured the day after in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)
Measured by Karolinska test
It will be measured the day after in six occasions (the first day, day 7, day, 14, day 21, day 28, day 35)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 19, 2024

Primary Completion (Actual)

April 12, 2024

Study Completion (Actual)

May 20, 2024

Study Registration Dates

First Submitted

February 15, 2024

First Submitted That Met QC Criteria

March 8, 2024

First Posted (Actual)

March 13, 2024

Study Record Updates

Last Update Posted (Actual)

June 24, 2024

Last Update Submitted That Met QC Criteria

June 21, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • UCAMCFE-00036

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sweat

Clinical Trials on Low intensity

Subscribe